In compliance with current regulations, let us know which audience you belong to:
Amsterdam, Netherlands / Bologna, Italy — October 5th 2023
Espansione Group, a pioneer in the medtech industry and an advocate for science-driven innovation, proudly unveils the first preliminary results of its recent multicentric, randomized controlled investigation: LightWave I.
These case reports underscore the transformative potential of LM® LLLT, the company’s patented photobiomodulation (PBM) technology currently being adopted in LightWave I to address dry Age-Related Macular Degeneration (AMD), a leading cause of visual impairment in the elderly.
Dr. Claudio Iovino (University of Naples L. Vanvitelli), one of the nine investigators involved in the study, provides additional context: “Age-related macular degeneration (AMD) is characterized by three stages: early, intermediate, and late (dry and wet). This relatively common retinal disorder progresses very slowly in some people and faster in others. Nevertheless, if a patient is affected by early-stage AMD, they may not even notice any visual loss for a long time before complications occur. LightWave I is an ongoing multicentric clinical trial focusing on patients with grade 2-3 AMD according to the AREDS classification, treated with photobiomodulation. The real goal of the study is to provide a treatment able to significantly slow down the progression to the advanced stages of the disease. The results of the study, starting with these case reports, may shed a new light on the management of AMD, with positive repercussion also on the healthcare system and its related economics.”
This view is further corroborated by Dr. Enrico Borrelli (IRCCS San Raffaele Hospital, Milan), who stated that “[...] the transition from early or intermediate age-related macular degeneration (AMD) to late-stage AMD, whether it's dry or neovascular, consistently leads to a substantial decline in visual acuity. Numerous risk factors, such as drusen volume, have been linked to this progression. Consequently, it becomes imperative to develop novel treatments targeted at mitigating this advancement and modifying these risk factors.”
The study, rooted in Espansione's relentless pursuit of scientific excellence and product innovation, opened up the possibility to share two distinct case reports deriving from the application of LM® LLLT with eye-light®.
While preliminary, these findings are not only indicative of eye-light® and LM® LLLT’s efficacy, but also a testament to Espansione's commitment to redefine patient care in ophthalmology.
“Low-level light therapy is a groundbreaking technology able to cure different eye diseases by acting at the root of the cellular dysregulation,” noted Prof. Giuseppe Giannaccare (University of Cagliari), another investigator involved in LightWave I. “From the first successful studies in the setting of ocular rosacea, MGD and other ocular surface diseases, this technology has been translated to the back of the eye where the perspective of halting the progression of dry age-related macular degeneration opens up a new fascinating scenario.”
Matteo Corbellino, Chief Marketing & Innovation Officer at Espansione Group, commented "These breakthroughs encapsulate what Espansione stands for, and our unyielding commitment to evidence-based progress. We're excited to be at the forefront of this industry-wide journey to redefine AMD treatment, and look forward to releasing more robust evidence of LM® LLLT’s ability to change people’s lives soon enough.”
The full press release (download link above+below, and by clicking the picture) includes two major case reports:
1. CASE #1
Describes a 68-year-old female patient with AMD (AREDS Category 3) witnessed an improvement in visual acuity from 50 to 55 ETDRS letters post-treatment.
2. CASE #2
Describes a 55-year-old male patient diagnosed with non-neovascular AMD observed a staggering rise in visual acuity from 25 to 60 ETDRS letters, accompanied by pronounced therapeutic effects at the cellular level.
Download the full case report now at the links at the top + bottom of the page.
LightWave I Case Reports © 2023 Espansione Group, All Rights Reserved
> ABOUT ESPANSIONE GROUP
Espansione Group is an established player in the medtech industry. Espansione Group strives to deliver the highest standard in the industry. Every day, the company invests heavily in researching and developing the Espansione Ecosystem to achieve its ambition: establishing new paradigms in ophthalmology and beyond, driven by its desire to provide its partners and their patients with the best, certified medical technologies, Light Modulation® Low-level Light Therapy (LM® LLLT) and Optimal Power Energy® Intense Pulsed Light (OPE® IPL). Present in over 50 countries, Espansione Group's aims to continue its strong growth in years to come, relentlessly focusing its efforts on research, development, and customer excellence.
For more information, visit www.espansionegroup.it
© 2023 Espansione Group, All Rights Reserved
Posted on October 5th, 2023 in Newsroom